Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-11-24
pubmed:abstractText
Patients with high viral load (> or =1.0 x 10(5) IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the HCV core region could affect virological non-response especially in patients who could not achieve HCV-RNA negativity during treatment. The present study evaluated 167 consecutive Japanese adults with high HCV genotype 1b viral load who received combination therapy for > or =24 weeks. A case-control study matched for age, sex, genotype, and viral load was conducted to investigate the predictive factors for virological non-response, especially absolute virological non-response (patients who could not achieve >2 log decline of HCV RNA from baseline during the initial 24 weeks of therapy). Virological non-response was identified in 26.3% of patients, and 45.5% of these were absolute virological non-responders. Multivariate analysis identified ribavirin dose <11.0 mg/kg, moderate-to-severe hepatocyte steatosis, and substitutions of aa 70 and/or 91 in the core region as significant independent factors associated with virological non-response. The majority of absolute virological non-responders had such substitutions in the core region (95.0%), as well as substitution of glutamine at aa 70 and/or methionine at aa 91 (90.0%). In the present work, such substitutions significantly affected the viral kinetics in virological non-responders. The results suggest that viral, host, and treatment-related factors determine the response to IFN/ribavirin combination therapy in patients with high HCV genotype 1b viral load, and that amino acid substitution patterns in the core region is potentially useful pretreatment predictor of virological non-response.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0146-6615
pubmed:author
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
83-90
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16299715-Adult, pubmed-meshheading:16299715-Aged, pubmed-meshheading:16299715-Amino Acid Substitution, pubmed-meshheading:16299715-Antiviral Agents, pubmed-meshheading:16299715-Case-Control Studies, pubmed-meshheading:16299715-Drug Therapy, Combination, pubmed-meshheading:16299715-Fatty Liver, pubmed-meshheading:16299715-Female, pubmed-meshheading:16299715-Genotype, pubmed-meshheading:16299715-Hepacivirus, pubmed-meshheading:16299715-Hepatitis C, pubmed-meshheading:16299715-Humans, pubmed-meshheading:16299715-Interferons, pubmed-meshheading:16299715-Male, pubmed-meshheading:16299715-Middle Aged, pubmed-meshheading:16299715-Mutation, Missense, pubmed-meshheading:16299715-RNA, Viral, pubmed-meshheading:16299715-Ribavirin, pubmed-meshheading:16299715-Risk Factors, pubmed-meshheading:16299715-Treatment Outcome, pubmed-meshheading:16299715-Viral Load
pubmed:year
2006
pubmed:articleTitle
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
pubmed:affiliation
Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan. akuta-gi@umin.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't